Xvivo Perfusion AB/Skr XVIVO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Xvivo Perfusion AB
Xvivo Perfusion AB is a biotechnology company specializing in the development and commercialization of medical devices and systems for organ transplantation. The company's core products include machine perfusion devices and solutions designed to preserve, evaluate, and transport donor organs, with a particular focus on lungs and hearts. Founded in 1998, Xvivo is headquartered in Gothenburg, Sweden, and has established a presence in key markets worldwide. The company's strategic positioning is enhanced by its commitment to improving transplantation outcomes through innovative technologies and research collaborations. Xvivo's expertise in organ preservation and perfusion technology provides competitive strengths in the field of regenerative medicine.
- Ticker
- Skr XVIVO
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 207
- Headquarters
- Mölndal, Sweden
- Website
- www.xvivogroup.com
XVIVO Metrics
BasicAdvanced
kr 6.5B
50.32
kr 4.09
1.47
-
Price and volume
Market cap
kr 6.5B
Beta
1.47
52-week high
kr 314.80
52-week low
kr 160.10
Average daily volume
102K
Financial strength
Current ratio
3.915
Quick ratio
2.689
Long term debt to equity
0.048
Total debt to equity
0.053
Profitability
EBITDA (TTM)
178.939
Gross margin (TTM)
71.17%
Net profit margin (TTM)
13.44%
Operating margin (TTM)
13.33%
Effective tax rate (TTM)
17.19%
Revenue per employee (TTM)
kr 4,630,000
Management effectiveness
Return on assets (TTM)
3.22%
Return on equity (TTM)
5.91%
Valuation
Price to earnings (TTM)
50.318
Price to revenue (TTM)
6.762
Price to book
2.85
Price to tangible book (TTM)
4.09
Price to free cash flow (TTM)
408.584
Free cash flow yield (TTM)
0.24%
Free cash flow per share (TTM)
0.504
Growth
Revenue change (TTM)
17.83%
Earnings per share change (TTM)
332.76%
3-year revenue growth (CAGR)
18.69%
10-year revenue growth (CAGR)
21.89%
3-year earnings per share growth (CAGR)
72.09%
10-year earnings per share growth (CAGR)
34.17%
What the Analysts think about XVIVO
Analyst ratings (Buy, Hold, Sell) for Xvivo Perfusion AB stock.
Analyst projections of the future price of Xvivo Perfusion AB stock.
Bulls say / Bears say
XVIVO’s momentum is strong: third-quarter sales rose 34% in SEK, with 32% organic growth, while EBITDA margin improved to 21% from 19%. Thoracic sales grew 51% and nine-month abdominal sales grew 21% in local currencies. (XVIVO Perfusion)
European CE certification makes XVIVO’s heart-preservation system available to transplant centres across Europe, opening a new commercial growth avenue. Clinical trial results showed fewer severe early complications than conventional ice storage, supporting the product’s potential value to transplant teams. (Inderes)
The US heart opportunity is advancing: the FDA received XVIVO’s PMA application, backed by the PRESERVE trial and follow-up evidence. The trial met its pre-specified primary endpoints, although US sales still depend on regulatory approval. (XVIVO Perfusion, XVIVO Perfusion)
The lung business faces customer-concentration risk: a large US customer may move part of its business to its own platform in 2027. Q3 thoracic sales also benefited from a customer inventory build, which may not recur at the same level. (Yahoo Finance)
Services remain a weak spot: third-quarter sales fell 28% and the segment recorded a negative 19% gross margin. The group’s gross margin also fell to 70% from 75%, reflecting service weakness alongside product mix and inventory write-downs. (XVIVO Perfusion, Yahoo Finance)
Heavy development spending is limiting cash left after investment: nine-month operating cash flow was SEK 181.8 million, but total cash flow was only SEK 1.9 million after SEK 131.7 million of R&D investment. Continued heart-product regulatory work could keep cash generation constrained as the company expands. (XVIVO Perfusion)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
XVIVO Financial Performance
Revenues and expenses
XVIVO Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing XVIVO
AllUSDEURGBP
Fund name | Fund size | Skr XVIVO weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.05% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.05% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.05% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.03% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.